TREATMENT OF URETHRAL RECURRENCE FOLLOWING RADICAL CYSTECTOMY AND ILEAL BLADDER SUBSTITUTION
- 1 September 2004
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 172 (3), 937-942
- https://doi.org/10.1097/01.ju.0000135626.91587.c8
Abstract
Purpose: With the introduction of orthotopic bladder substitution after radical cystectomy in patients with invasive bladder cancer urethral recurrences have become a therapeutic challenge. Materials and Methods: We retrospectively evaluated our patients with urethral recurrences treated with a urethra sparing approach after orthotopic bladder substitution. Depending on the extension of recurrence and eventual concomitant metastases patients were treated with urethrectomy, no treatment, systemic chemotherapy or intraurethral bacillus Calmette-Guerin (BCG). Three times the common dose of BCG (ImmuCyst, Aventis, Paris, France or OncoTICE, Organon, West Orange, New Jersey) in 150 ml NaCl 0.9% was used for intraurethral BCG perfusion therapy according to an institutional protocol using a modified Foley catheter. This regimen was repeated weekly for 6 weeks and patients were followed prospectively. Results: Between 1985 and 2001, 15 of 371 patients (4%) who received an orthotopic bladder substitute had urethral recurrence. Two patients were treated with systemic chemotherapy (methotrexate, vinblastine, doxorubicin and cisplatin) alone due to metastatic disease and 10 received intraurethral BCG therapy. Five of 6 patients (83%) with carcinoma in situ remained free of recurrence following treatment with BCG, while in 4 with papillary or invasive disease treatment failed. Three patients underwent urethrectomy, including 2 following failed BCG therapy for papillary disease. Conclusions: Carcinoma in situ urethral recurrence following orthotopic bladder substitution can be treated successfully with intraurethral BCG perfusion therapy in approximately 80% of patients. However, papillary and invasive transitional cell urethral recurrence should be treated with urethrectomy.Keywords
This publication has 16 references indexed in Scilit:
- Postoperative morbidity, functional results and quality of life of patients following orthotopic neobladder reconstructionInternational Journal of Urology, 2003
- Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion.World Journal of Urology, 2000
- DOES PROSTATE TRANSITIONAL CELL CARCINOMA PRECLUDE ORTHOTOPIC BLADDER RECONSTRUCTION AFTER RADICAL CYSTOPROSTATECTOMY FOR BLADDER CANCER?Journal of Urology, 1997
- Urethral Recurrence in Patients with Orthotopic Ileal NeobladdersJournal of Urology, 1996
- MANAGEMENT OF THE PATIENT WITH BLADDER CANCERUrologic Clinics of North America, 1994
- The Ileal Neobladder: 6 Years of Experience with more than 200 PatientsJournal of Urology, 1993
- Selective Urethrectomy Following Cystoprostatectomy for Bladder CancerJournal of Urology, 1986
- Indications for Ureterectomy in Men Undergoing Single Stage Radical Cystectomy for Bladder CancerJournal of Urology, 1984
- Urethral cytology following cystectomy for bladder carcinomaThe American Journal of Surgical Pathology, 1977
- URETHRAL CARCINOMA ASSOCIATED WITH CANCER OF THE BLADDER1BJU International, 1960